LBA72 NorthStar: A phase II randomized study of osimertinib (OSI) with or without local consolidative therapy (LCT) for metastatic EGFR-mutant non-small cell lung cancer (NSCLC)

Y.Y. Elamin, S. Gandhi, M. Antonoff, D. Gibbons, M.V. Negrao, T. Cascone, C.M. Gay, L.A. Byers, George R. Blumenschein, Chad G. Rusthoven, A. Vaporciyan, C. Blakely, Daniel R. Gomez, Lei Feng, J. Zhang, Mehmet Altan, X. Le, Jingyao Chang, S. Swisher, J. Heymach